Not Yet Recruiting OBSERVATIONAL NCT03663153

SEMA4C as a Relapse Biomarker in Breast Cancer

Sponsor: Hubei Cancer Hospital

Interventions SEMA4C high value follow-up group SEMA4C low value follow-up group

Updated 8 times since 2018 Last updated: Oct 6, 2021 Started: Sep 1, 2022 Primary completion: Aug 1, 2023 Completion: Aug 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Breast Cancer and is currently actively recruiting participants. Hubei Cancer Hospital leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Dec 2021 — Jul 2024 [monthly]

Not Yet Recruiting
Nov 2021 — Dec 2021 [monthly]

Not Yet Recruiting
Oct 2021 — Nov 2021 [monthly]

Not Yet Recruiting

▶ Show 3 earlier versions

Jan 2021 — Oct 2021 [monthly]

Not Yet Recruiting
Nov 2020 — Jan 2021 [monthly]

Not Yet Recruiting
Oct 2018 — Nov 2020 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hubei Cancer Hospital
Qilu Hospital of Shandong University
The First Affiliated Hospital with Nanjing Medical University
The First People's Hospital of Jingzhou
Tongji Hospital
Wuhan Central Hospital
Xiangyang Central Hospital

Data source: Tongji Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.